-
CAP Authoritative Voice: What to deal with when MSI and MMR test results are inconsistent
Time of Update: 2022-10-06
The first statement states that if inconsistent results occur, pathologists should interpret as positive for any evidence that proves mmR defects by immunohistochemistry (IHC) for DNA mismatch repair defects (dMMR) or by second-generation sequencing (NGS) or polymerase chain reaction (PCR) methods that prove to be MMR defects, thereby making patients eligible for immunotherapy.
-
Prof. Shu Yongqian: For the treatment of the EGFR-sensitive mutation NSCLC, I am more likely to choose vometinib
Time of Update: 2022-10-06
At present, three third-generation EGFR targeted therapy drugs have been approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with classical mutations in EGFR, includin
-
ESMO Prospect The next generation of immunological innovation therapies, who can take the baton?
Time of Update: 2022-10-03
The 2022 European Society for Internal Oncology (ESMO) Annual Meeting will be held in Paris from September 9 to 13 local time. At present, ESMO has announced the conference schedule, as one of the mos
-
"Medical Voice Her Style" No. 2 Inheriting the past and passing on the temperature of medicine
Time of Update: 2022-10-03
In the early autumn, the golden wind is refreshing, the heart is full of Haoyue, and the teacher is respected. Pushing open the door of medical truth, they have a Dan heart, a cold and hot body, and
-
"Chinese characteristics" lung cancer general screening model announced! No risk factors should also be screened
Time of Update: 2022-10-03
*For medical professionals only2022 ESMO Voice of China – Professor Liang Wenhua interprets a new perspective on lung cancer screeningIn China, the incidence and mortality rate of lung cancer ranks fi
-
To treat the most dangerous breast cancer, the Huaxi team jointly targeted MEK and proteasomes to provide new ideas
Time of Update: 2022-10-03
▲AZD6244 (10mg/kg) + MG132 (2mg/kg) combined to reduce tumor volume and weight (image source: reference [1]) In summary, this study provides a new idea of combining targeted proteasomes and MEK for the clinical treatment of triple-negative breast cancer, and reveals the degradation of PDPK1 mediated by inhibiting proteasomes and activating autophagy to enhance the mechanism of sensitivity of triple-negative breast cancer cells to MEK inhibitors.
-
Allogeneic memory NK cell therapy exhibits excellent tumor resistance or can overcome solid tumor obstruction
Time of Update: 2022-10-03
September 18, 2022 / Medical Mack News eMedClub News /-Recently, cell therapy company Wugen presented preclinical data from the company's NK cell therapy WU-NK-101 at the ESMO conference, which shows that WU-NK-101 has strong tumor toxicity and may overcome the limitations of current cell therapy and become a potential clinical means of solid tumor treatment.
-
World Lymphoma Day 2022: Courage to go to work together to help lymphoma patients return to society
Time of Update: 2022-10-03
On the occasion of World Lymphoma Day, the "Born of Beauty" World Lymphoma Day public education activity supported by Lymphoma House and Roche Pharmaceutical China has set sail again, and the theme of
-
Nearly double the 5-year survival rate! Immunotherapy sets a new high for ESMO in 2022
Time of Update: 2022-10-03
The results showed that pabolizumab + pemetrexed + platinum significantly increased the OS rate of patients with metastatic non-squamous NSCLC in the initial treatment compared with placebo + pemetrexed + platinum, and did not cause EGFR/ALK changes.
-
Academician Fan Jia of Fudan University and other teams have published 10 articles in Hepatology and STTT, making important progress in the field of hepatocellular carcinoma
Time of Update: 2022-10-03
On September 16, 2022, Fan Jia and Gao Qiang of Fudan University published a research paper entitled "Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma" online at Autophagy (IF=13).
-
ESMO directly attacks the immunoneoadjuvant therapy vs adjuvant therapy, and the perioperative exploration of melanoma
Time of Update: 2022-10-03
The first data presented at this ESMO conference from the Phase II SWOG S1801 study evaluated the use of neoadjuvant therapy (NAT) versus adjuvant therapy (AT) for resectable patients with stage III-IV melanoma.
-
IDH wild-type diffuse glioma versus typical glioblastoma
Time of Update: 2022-10-03
Hayato Suzuki et al. of Akita University Hospital in Japan found that IDHwt diffuse glioma lacks molecular characteristics of glioblastoma except for PI3K/MAPK pathway gene mutations; The results were
-
ESMO Direct Strike Unresectable NSCLC: After IMRT, Duvalizumab is 80% used!
Time of Update: 2022-10-03
Table Radiation dose and incidence of pneumonia Table Major adverse events 4 Discussion and conclusion Previous studies have shown that the proportion of patients who are not suitable for duvalizumab after deterministic CRT is 23-30%.
-
ESMO Direct Attack The incidence of the most common recurrence sites of IB-IIIA stage NSCLC is as low as 6%: ADAURA Heavy Update
Time of Update: 2022-10-03
2 Methods Eligible patients (18 years of age [20 years in Japan/Taiwan], WHO PS 0/1, complete resection of EGFR-sensitive mutations, IB-IIIA staging [AJCC 7th edition] NSCLC, adjuvant chemotherapy allowed) were randomized to receive ositinib (80 mg once daily) or placebo (3 years) in a 1:1 ratio.
-
ESMO directly hit the rare target and there is also a breakthrough! The results of the KRYSTAL-1 study in coloral cancer are available
Time of Update: 2022-10-03
Figure 2 Patient baseline features>>>>Efficacy and safety analysis of monotherapyA total of 43 patients were able to assess efficacy, as shown in Figure 3, patients had an ORR of 19%, a disease control rate (DCR) of 86%, and a median duration of remission (DOR) of 4.
-
"Chinese Group Liver Cancer Screening Guidelines (2022, Beijing)" released!
Time of Update: 2022-10-03
Question 16: Recommendations for common surveillance programs for liver cancer: Based on the multi-dimensional evidence of the effectiveness, safety, accessibility and economy of monitoring in high-risk populations of liver cancer, it is recommended to use US combined AFP detection as a monitoring technology in the Chinese population, with a monitoring interval of 12 months, of which the recommended monitoring interval for patients with chronic liver disease (including cirrhosis, chronic hepatitis, etc.
-
Efficiently distinguishing between good and malignant lung nodules, this new method may be tried
Time of Update: 2022-10-03
Figure 4 PulmoSeek Plus model clinical net benefit study results Finally, Professor Liang pointed out: "This study shows that DNA methylation, clinical features and imaging features multi-dimensional biomarkers combined to diagnose good and malignant lung nodules, which not only have high accuracy, but also reduce the burden on patients, which is worth using in subsequent clinical decisions.
-
Good drug first, drug-resistant worry-free ositinib first-line resistance - HER2 amplification/mutation response strategy
Time of Update: 2022-10-03
In addition, a phase II "basket" study found that in 18 patients with HER2 mutant lung cancer who received multi-line therapy, the ORR treated with T-DM1 was 44% and the median PFS was 5 months [19].
-
ESMO Strikes Directly at the First Prospective Study: An Exploration of the Mechanism of Oshitinib Resistance
Time of Update: 2022-10-03
Details are as follows:Professor Zofia Piotrowska1 backgroundThird-generation EGFR TKI ositinib is the preferred first-line treatment for patients with advanced NSCLC with EGFR mutation.
Details are as follows:Professor Zofia Piotrowska1 backgroundThird-generation EGFR TKI ositinib is the preferred first-line treatment for patients with advanced NSCLC with EGFR mutation.
-
ESMO Direct Verbal Report Phase III Study: How to Choose Adjuvant Therapy for Resectable NSCLC?
Time of Update: 2022-10-03
Details are as follows: Phase III KEYNOTE-091 study subgroup analysis Professor Solange Peters background Patients with complete resection of stage IB (T 4cm) to IIIA NSCLC (AJCC v7) can receive ≤ 4 cycles of adjuvant chemotherapy according to the PEARLS/KEYNOTE-091 study as recommended by local guidelines.
